Author | Study description | Treatment | Patient population | % 1L | % 2L | % 3L+ | N | ORR % | PFS months | OS months | % TNBC patients |
---|---|---|---|---|---|---|---|---|---|---|---|
Tutt et al. [19] | Phase III TNT | Car | 2L+ mTNBC | Â | 100 | 59 | 31.4 | 3.1 | 12.4 | 100 | |
Doc | Â | Â | Â | 64 | 34.0 | 4.5 | 12.3 | 100 | |||
Phase II LOTUS | Pac+Ipatasertib | 1L mTNBC | 100 | Â | Â | 62 | NR | 6.2 | NR | 100 | |
Pac | 1L mTNBC | 100 | Â | Â | 62 | NR | 4.9 | NR | 100 | ||
Schmid et al. [10] | Phase III IMpassion130 | Atezolizumab plus nab-paclitaxel | 1L mTNBC | 100 | Â | Â | 451 | NR | 7.2 | 21.3 | 100 |
nab-paclitaxel | 1L mTNBC | 100 | Â | Â | 451 | NR | 5.5 | 17.6 | 100 | ||
Phase III OLYMPIAD | Olaparib | 1L–2L mBC |  | 100 | 205 | NR | 7.0 | 19.3 | 49.8 | ||
Physician’s-Choice | 1L–2L mBC |  |  |  | 97 | NR | 4.2 | 17.1 | 49.5 | ||
Litton et al. [16] | Phase III EMBRACA | Talazoparib | 2L+ locally advanced BC | Â | 100 | 287 | 62.6 | 8.6 | NR | 45.3 | |
Physician’s-Choice | 2L+ locally advanced BC |  |  |  | 144 | 27.2 | 5.6 | NR | 41.7 |